These Were the 2 Worst-Performing Stocks in the Nasdaq-100 in May 2025

The Nasdaq-100 market index holds a lot of volatile stocks. Some of its top performers seem overvalued today, while others seem to have room for further growth. The index as a whole rose 9.1% last month, outpacing the S&P 500 (SNPINDEX: ^GSPC) return of 6.3%.

But what about the other end of the spectrum? Let's take a quick look at the two worst performers on the Nasdaq-100 in May 2025.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

Regeneron: Down 18% in May

Biotech giant Regeneron (NASDAQ: REGN) was on track for a quiet May, holding almost exactly steady with just a couple of days left in the month. A disappointing earnings report changed that story in a hurry, driving Regeneron's stock 18% lower on the last trading day in May.

Regeneron's first-quarter sales fell 4% year over year, while adjusted earnings per share dropped 14% lower.

This is one of the most affordable large-cap biotech stocks today, but arguably for good reasons. The stock is down 48% over the last year, so I understand if you want to buy the dip. Just remember that the company is facing unprecedented challenges right now, and a strong development pipeline doesn't always result in blockbuster products.

Image source: Getty Images.

Copart: Down 15.6% in May

Online auto auction specialist Copart (NASDAQ: CPRT) also fell after reporting earnings in May. All the headline numbers were up year over year and roughly in line with analyst expectations, but market makers were looking for something more. Copart's stock trades at lofty valuation multiples such as 10.6 times sales and 33 times earnings. It doesn't take much of a miss to inspire a large price drop under these conditions.

Copart's stock is down 5% over the last year, but it remains a long-term winner with a market-beating three-year return and a stellar 1,030% gain over the last decade. Management argues that the company might benefit from tariff-based uncertainty, as expensive repair parts could result in more "total loss" insurance claims. If so, Copart's stock may be a great buy today -- but only time will tell how this theory works out.

Should you invest $1,000 in Regeneron Pharmaceuticals right now?

Before you buy stock in Regeneron Pharmaceuticals, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Regeneron Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $888,780!*

Now, it’s worth noting Stock Advisor’s total average return is 999% — a market-crushing outperformance compared to 174% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of June 9, 2025

Anders Bylund has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Copart and Regeneron Pharmaceuticals. The Motley Fool has a disclosure policy.